Stryker (NYSE:SYK) Shares Down 6.2% – What’s Next?

Stryker Corporation (NYSE:SYK) shares fell 6.2% on Tuesday . The company traded as low as $286.28 and last traded at $284.2830. Approximately 852,923 shares were traded during mid-day trading, a decline of 64% from the average session volume of 2,347,572 shares. The stock had previously closed at $303.13.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Leerink Partners lowered their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Truist Financial lifted their price objective on Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a report on Friday, July 31st. UBS Group began coverage on shares of Stryker in a research note on Tuesday, July 28th. They set a “buy” rating and a $400.00 target price on the stock. Citizens Jmp reduced their price target on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research note on Monday, August 3rd. Finally, Wolfe Research downgraded shares of Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Price Performance

The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company has a market capitalization of $107.57 billion, a P/E ratio of 29.08, a price-to-earnings-growth ratio of 1.90 and a beta of 0.76. The firm’s 50-day moving average is $328.30 and its 200-day moving average is $329.01.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts predict that Stryker Corporation will post 15.03 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.3%. Stryker’s dividend payout ratio (DPR) is 36.48%.

Insider Activity at Stryker

In other news, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider owned 6,102 shares in the company, valued at $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Stryker

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Cornerstone Financial Management LLC raised its stake in Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after purchasing an additional 31 shares during the period. Amundi boosted its stake in Stryker by 18.3% in the 2nd quarter. Amundi now owns 1,246,353 shares of the medical technology company’s stock worth $392,402,000 after purchasing an additional 192,447 shares during the period. HighTower Advisors LLC grew its holdings in Stryker by 8.3% during the 2nd quarter. HighTower Advisors LLC now owns 486,005 shares of the medical technology company’s stock valued at $153,014,000 after buying an additional 37,269 shares in the last quarter. Advus Financial Partners LLC increased its holdings in Stryker by 25.1% in the 2nd quarter. Advus Financial Partners LLC now owns 802 shares of the medical technology company’s stock valued at $253,000 after acquiring an additional 161 shares during the last quarter. Finally, Groupe la Francaise grew its holdings in Stryker by 16.7% during the 2nd quarter. Groupe la Francaise now owns 21,000 shares of the medical technology company’s stock valued at $6,613,000 after buying an additional 3,000 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.